Trial Profile

A Phase II Study of Cemiplimab, an Anti-PD-1 Monoclonal Antibody, and ISA101b Vaccine in Patients With Recurrent/Metastatic HPV16 Positive Oropharyngeal Cancer Who Have Experienced Disease Progression With Prior Anti-PD-1 Therapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary) ; Peltopepimut-S (Primary)
Indications Carcinoma; Head and neck cancer; Oropharyngeal cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms ProcemISA
Sponsors ISA Pharmaceuticals

17 Apr 2024 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
12 Apr 2024 This trial has been completed in Czechia and Belgium (End Date: 5 Apr 2024), according to European Clinical Trials Database record.
12 Jan 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com